WallStreetZenWallStreetZen

NASDAQ: INMB
Inmune Bio Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their INMB stock forecasts and price targets.

Forecast return on equity

Is INMB forecast to generate an efficient return?

Company
95.93%
Industry
19.69%
Market
167.82%
INMB's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is INMB forecast to generate an efficient return on assets?

Company
72.76%
Industry
23.76%
INMB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

INMB earnings per share forecast

What is INMB's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$0.56
Avg 2 year Forecast
-$0.79
Avg 3 year Forecast
-$0.80

INMB revenue forecast

What is INMB's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$9.7M
Avg 3 year Forecast
$24.4M

INMB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
INMB$2.18N/AN/A
HRTX$0.32N/AN/AHold
HYFT$1.31$5.00+281.68%Strong Buy
INKT$11.71$35.00+198.89%Buy
XLO$9.04N/AN/A
View Top Biotech Stocks

Inmune Bio Stock Forecast FAQ

What is INMB's earnings growth forecast for 2026-2028?

(NASDAQ: INMB) Inmune Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.34%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.18%.

Inmune Bio's earnings in 2026 is -$18,416,000.On average, 6 Wall Street analysts forecast INMB's earnings for 2026 to be -$15,569,876, with the lowest INMB earnings forecast at -$18,223,138, and the highest INMB earnings forecast at -$12,530,836. On average, 5 Wall Street analysts forecast INMB's earnings for 2027 to be -$21,797,826, with the lowest INMB earnings forecast at -$30,190,572, and the highest INMB earnings forecast at -$12,530,836.

In 2028, INMB is forecast to generate -$22,080,915 in earnings, with the lowest earnings forecast at -$35,630,314 and the highest earnings forecast at -$7,285,370.

If you're new to stock investing, here's how to buy Inmune Bio stock.

What is INMB's revenue growth forecast for 2026-2028?

(NASDAQ: INMB) Inmune Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.55%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.69%.

Inmune Bio's revenue in 2026 is $0.On average, 6 Wall Street analysts forecast INMB's revenue for 2026 to be $0, with the lowest INMB revenue forecast at $0, and the highest INMB revenue forecast at $0. On average, 5 Wall Street analysts forecast INMB's revenue for 2027 to be $270,072,121, with the lowest INMB revenue forecast at $106,074,982, and the highest INMB revenue forecast at $442,367,643.

In 2028, INMB is forecast to generate $676,887,160 in revenue, with the lowest revenue forecast at $432,459,540 and the highest revenue forecast at $930,223,746.

What is INMB's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: INMB) forecast ROA is 72.76%, which is higher than the forecast US Biotechnology industry average of 23.76%.

What is INMB's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: INMB) Inmune Bio's current Earnings Per Share (EPS) is -$0.67. On average, analysts forecast that INMB's EPS will be -$0.56 for 2026, with the lowest EPS forecast at -$0.66, and the highest EPS forecast at -$0.45. On average, analysts forecast that INMB's EPS will be -$0.79 for 2027, with the lowest EPS forecast at -$1.09, and the highest EPS forecast at -$0.45. In 2028, INMB's EPS is forecast to hit -$0.80 (min: -$1.28, max: -$0.26).

What is INMB's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: INMB) forecast ROE is 95.93%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.